J&J ends Palomar deal
This article was originally published in The Gray Sheet
Palomar says it will move forward with commercialization of its home-use, light-based technology for treatment of cellulite, skin aging and acne after Johnson & Johnson backed out of an agreement to market the product, citing economic conditions. The Burlington, Mass.-based firm received 510(k) clearance for the device for treatment of periorbital wrinkles in June (1"The Gray Sheet" June 15, 2009). Citing a multi-billion dollar market opportunity, Palomar CEO Joseph Caruso said the firm plans to launch the device for multiple applications in the second half of 2010. Near-term marketing efforts will focus on "certain specialty channels," Caruso said
You may also be interested in...
Palomar Medical Technologies gains 510(k) clearance June 5 for an over-the-counter, home-use laser for treatment of periorbital wrinkles - the first clearance of its kind, according to the company. The product will be marketed directly to consumers without a prescription by Johnson & Johnson under an existing agreement (1"The Gray Sheet" Sept. 13, 2004, p. 25). The device will enable laser wrinkle reduction "for a fraction of the cost" of similar treatments in the professional setting, according to Palomar
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.